| 1例螺内酯致男性肝硬化患者乳房发育的不良反应分析 |
| |
| 引用本文： | 孙钟慧,王铀,段海洁,谭月桂,梁乐,姚鸿萍.1例螺内酯致男性肝硬化患者乳房发育的不良反应分析[J].药学实践杂志,2017,35(2):165-166,170. |
| |
| 作者姓名： | 孙钟慧 王铀 段海洁 谭月桂 梁乐 姚鸿萍 |
| |
| 作者单位： | 西安交通大学第一附属医院药学部, 陕西 西安 710061;西安市第五医院药学部, 陕西 西安 710082,西安市第五医院药学部, 陕西 西安 710082,西安市第五医院药学部, 陕西 西安 710082,西安市第五医院药学部, 陕西 西安 710082,西安市第一医院药学部, 陕西 西安 710002,西安交通大学第一附属医院药学部, 陕西 西安 710061 |
| |
| 摘 要： | 目的 分析1例男性肝硬化患者服用螺内酯后出现乳房发育的不良反应，探索可能原因，提高药学服务水平。方法 临床药师结合患者的基础疾病、用药史等诊疗经过，查找国内外相关文献，对不良反应产生原因进行分析。结果 患者停用螺内酯后，乳房疼痛减轻至消失，推测螺内酯是导致患者乳房发育的可疑药物。结论 临床药师通过关注药品不良反应，可以为临床提供药物信息和更好的药学服务。
|
| 关 键 词： | 螺内酯 肝硬化 乳房发育 药品不良反应 |
| 收稿时间： | 2016/9/6 0:00:00 |
| 修稿时间： | 2017/1/5 0:00:00 |
A case study of spironolactone induced gynecomastia in one male patient with cirrhosis |
| |
| SUN Zhonghui,WANG You,DUAN Haijie,TAN Yuegui,LIANG Le and YAO Hongping.A case study of spironolactone induced gynecomastia in one male patient with cirrhosis[J].The Journal of Pharmaceutical Practice,2017,35(2):165-166,170. |
| |
| Authors: | SUN Zhonghui WANG You DUAN Haijie TAN Yuegui LIANG Le and YAO Hongping |
| |
| Institution: | Department of Pharmacy, First Hospital Affiliated to Xi''an Jiaotong University, Xi''an 710061, China;Department of Pharmacy, No.5 Hospital of Xi''an City, Xi''an 710082, China,Department of Pharmacy, No.5 Hospital of Xi''an City, Xi''an 710082, China,Department of Pharmacy, No.5 Hospital of Xi''an City, Xi''an 710082, China,Department of Pharmacy, No.5 Hospital of Xi''an City, Xi''an 710082, China,Department of Pharmacy, No.1 Hospital of Xi''an City, Xi''an 710002, China and Department of Pharmacy, First Hospital Affiliated to Xi''an Jiaotong University, Xi''an 710061, China |
| |
| Abstract: | Objective To study one male patient with cirrhosis for spironolactone induced gynecomastia and promote clinical pharmacists providing better pharmaceutical cares.Methods Based on the patient''s diseases and medication history, clinical pharmacists searched related literature and analyzed the cause of gynecomastia for the patient.Results The patient''s breast pain was relieved and finally disappeared after termination of spironolactone. Therefore, spironolactone was suspected to be the drug to cause gynecomastia.Conclusion Clinical pharmacists can improve pharmaceutical cares by carefully monitoring the adverse reactions and selecting appropriate medications. |
| |
| Keywords: | spironolactone cirrhosis gynecomastia adverse drug reactions |
|
| 点击此处可从《药学实践杂志》浏览原始摘要信息 |
| 点击此处可从《药学实践杂志》下载免费的PDF全文 |
|
